QuidelOrtho Corp
QDEL Nasdaq· In Vitro & In Vivo Diagnostic Substances
Last close · Oct 23, 2026
$13.73
KIRA · Stoqly’s AI analyst, in plain words
- QuidelOrtho Corp had $2.7B of revenue in fiscal 2025, down 1.9% on the year before. Over five years, revenue changed +10.4% a year on average.
- Its operating margin was −33.7%, up 36.8 pts: of every 100 in sales, about −34 is left after running the business.
- QuidelOrtho Corp lost $1.1B in fiscal 2025.
- Free cash flow was −$83.0M in fiscal 2025, −3.0% of revenue.
- QuidelOrtho Corp returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 0.9%.
- QuidelOrtho Corp owes $2.7B more than it holds in cash.
Market cap
$938M
P/E
—
Revenue
$2.7B
Net income
−$1.1B
Free cash flow
−$83.0M
Operating margin
−33.7%
QuidelOrtho Corp in 30 seconds · fiscal 2025
Are sales growing?
−1.9%
No. Sales fell 1.9% last year.
Does it make a profit?
−41.5%
No. It lost money last year.
Does profit turn into cash?
−3.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What QuidelOrtho Corp does
No business description yet.
- Fiscal year ends
- December 28, 2025
- Latest annual report
- 10-K · Feb 19, 2026
- Legal name
- QuidelOrtho Corp
- CIK
- 0001906324
QuidelOrtho Corp · QDEL
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.7B | $3.3B | $3.0B | $2.8B | $2.7B |
| Revenue growth | 2.2% | 92.3% | −8.2% | −7.2% | −1.9% |
| Net interest income | −$5.8M | −$75.7M | −$148M | −$164M | — |
| Operating margin | 53.3% | 25.8% | 4.6% | −70.5% | −33.7% |
| Net income | $704M | $549M | −$10.1M | −$2.1B | −$1.1B |
| Net margin | 41.5% | 16.8% | −0.3% | −73.7% | −41.5% |
| Diluted EPS | $16.43 | $9.56 | −$0.15 | −$30.54 | −$16.69 |
| Cash | |||||
| Cash from operations | $806M | $885M | $280M | $83.0M | $105M |
| Capital expenditure | $293M | $141M | $209M | $195M | $188M |
| Free cash flow | $513M | $744M | $70.9M | −$112M | −$83.0M |
| FCF margin | 30.2% | 22.8% | 2.4% | −4.0% | −3.0% |
| Share buybacks | $104M | $74.3M | $7.2M | $0.0M | $0.0M |
| Share count change | −1.6% | 33.8% | 16.4% | 0.6% | 0.9% |
| Debt and strength | |||||
| Cash and short-term investments | $829M | $345M | $167M | $98.3M | $170M |
| Debt incl. finance leases | $1.3M | $2.9B | $2.6B | $2.8B | $2.9B |
| Shareholders' equity | $1.9B | $4.9B | $5.0B | $3.0B | $1.9B |
| Net debt / EBITDA | −0.9x | 2.2x | 4.0x | — | — |
| Current ratio | 4.5x | 1.6x | 1.6x | 1.2x | 1.5x |
| Interest coverage | — | 11.1x | 0.9x | −12.0x | −5.2x |
| Returns and quality | |||||
| Return on capital | 64.3% | 8.4% | 1.5% | −27.1% | −15.7% |
| Return on equity | 43.2% | 16.0% | −0.2% | −51.4% | −46.1% |
| Return on tangible equity | 47.1% | — | — | — | — |
| Piotroski F-score | — | 3 | 4 | 3 | 5 |
| Altman Z'' | 11.8 | 3.2 | 2.8 | −0.8 | −0.6 |
Insiders bought, 12 months
$1.2M
6 insiders
Insiders sold, 12 months
$0.1M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
QuidelOrtho Corp · QDEL
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $13.73 a share, the company is worth $938M.
Source: SEC EDGAR XBRL filings (CIK 0001906324). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.